A Multicenter Randomized Clinical Trial to Study the Effects of Single Doses of MK-8351 on the Early Asthmatic Response to a Lung Allergen Challenge
Latest Information Update: 12 May 2022
At a glance
- Drugs MK 8351 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 29 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 22 Aug 2013 New trial record